Pharmacoepidemiology is the study of medication utilisation, safety and effectiveness in different population groups. We analyse ‘big data’ to generate new evidence to improve clinical and policy decision making. Our research is multidisciplinary in nature and is conducted in partnership with leading clinicians.

We have expertise in analyses of medication data from cohort studies, clinical registries and administrative databases. This includes analyses of Australian Pharmaceutical Benefit Scheme (PBS) and electronic medical record data.

Our research investigates the ‘real world’ safety and effectiveness of medications for vulnerable population groups who are often excluded from randomised controlled trials (e.g. people with dementia, residents of aged care homes).

We lead and participate in a series of international collaborations with other world-leading research groups, including the Optimising Geriatric Pharmacotherapy through Pharmacoepidemiology Network (OPPEN) and Neurodegenerative Diseases Global Epidemiology Network (NeuroGEN).

Key therapeutic areas

  • aged care
  • asthma and chronic obstructive pulmonary disease
  • dementia
  • diabetes
  • cardiovascular disease
  • mental health

Principal investigator